A Phase 3 interventional study of Sodium zirconium cyclosilicate and Placebo in Hyperkalaemia, Metabolic Acidosis and Chronic Kidney Disease, sponsored by AstraZeneca. Terminated at 30 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 22nd largest by enrollment, is one of 9 that started in 2021, is one of 12 in phase 3, and was the 14th registered.
134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.
Browse Hyperkalemia studies →3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:
AstraZeneca · Sites in India
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Qianfoshan Hospital
Ages 18–75
By country, each count listing its studies:
sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 13 · Phase 4 6
First in 2014; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 88 across 103 interventional studies indexed under Hyperkalemia.
Median enrollment 120 across the 27 interventional studies. Of the 22 that completed or were terminated, 18 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
39 studies in Hyperkalemia by AstraZeneca: 2 open now, 3 under way, 1 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 39 studies in Hyperkalemia by AstraZeneca, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2021, is one of 13 in phase 3, and was the 23rd registered.
AstraZeneca’s Hyperkalemia studies by the year they started, since 2011.
2 of the studies testing sodium zirconium cyclosilicate in Hyperkalemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06736184Qianfoshan HospitalThe Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | 2026-12-31 |
| NCT07944378AstraZenecaA Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, from their registry updates:
Among AstraZeneca’s 39 in Hyperkalemia:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the efficacy of SZC as compared to placebo in maintaining normal sK+ in patients with hyperkalemia and metabolic acidosis associated with CKD
NEUTRALIZE is a prospective, randomized, double-blind, placebo-controlled, parallel, multicenter, Phase IIIb study to investigate the safety and efficacy of SZC in patients with hyperkalemia and low bicarbonate (metabolic acidosis ).
The study will be conducted in the United States (US) at approximately 35 investigative sites.
After screening on Day 1, all eligible patients will receive open-label SZC for up to 48 hours. Patients who achieve normokalemia within 48 hours will be randomized 1:1 into the double-blind randomized treatment phase to receive SZC or placebo. Study treatment will end with the Day 29 visit, which will be followed by a follow-up visit 7 days after the last administration of study medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization. Patients with POCT K+ \<3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol.
Drug: Sodium zirconium cyclosilicate · Drug: Placebo
Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
Drug: Sodium zirconium cyclosilicate · Drug: Placebo
Investigational medicinal product
Also known as: SZC
Plabeco comparator
Occurrence (Yes/no) of Participants Having Normal Serum Potassium (sK+) Between 3.5 and 5.0 mmol/L Inclusive at End of Treatment (EOT) Without Need for Rescue Treatment for Hyperkalemia at Any Point During the Randomized Phase
Response was defined as a subject having serum potassium (sK+) within 3.5-5.0 mmol/L at the EOT visit, and no use of rescue therapy for hyperkalaemia at any point during the randomized placebo-controlled period. Participants who used rescue therapy for hyperkalaemia at any point during the randomized placebo-controlled period were assigned a non-response. Participants who died prior to the EOT visit were treated as non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing.
Time frame: Day 1 of randomization phase to Day 29
Mean Serum Bicarbonate at Day 29
Least-squares mean calculated with a repeated measures analysis of covariance model where the dependent variable was post randomization serum bicarbonate and with fixed terms for randomized treatment group and serum bicarbonate.
Time frame: Day 29
Occurrence (Yes/no) of Participants Having an Increase in Serum Bicarbonate of Greater Than or Equal to 3 mmol/L From Baseline to EOT Without Need for Rescue Treatment for Metabolic Acidosis (Low Bicarbonate)
Occurrence (yes/no) of participants having an increase in serum bicarbonate of greater than or equal to 3 mmol/L from baseline (Day 1) to EOT (Day 29) without need for rescue treatment for metabolic acidosis (low bicarbonate). Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 3 mmol/L at the EOT visit without the need for rescue therapy for low bicarbonate. Participants who used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
Time frame: Day 1 to Day 29 of randomization phase
Occurrence (Yes/no) of Participants Having Serum Bicarbonate ≥22 mmol/L
Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 22 mmol/L at the EOT visit without the need for rescue therapy for low bicarbonate. Participants who had used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who died prior to the EOT visit were assigned a non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor.
Time frame: Day 1 to Day 29 of randomization phase
Occurrence (Yes/no) of Participants Having an Increase in Serum Bicarbonate of Greater Than or Equal to 2 mmol/L From Baseline (Day 1) to EOT Without Need for Rescue Treatment for Metabolic Acidosis (Low Bicarbonate)
Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 2 mmol/L at the EOT visit and no use of rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period. Participants who used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
Time frame: Day 1 to Day 29 of randomization phase
Participants Having Normal sK+ at EOT and an Increase in Serum Bicarbonate of ≥3 mmol/L From Baseline Without Need for Rescue Treatment for Metabolic Acidosis (Low Bicarbonate) or Hyperkalemia
Participants with normal sK+ between 3.5 and 5.0 mmol/L inclusive at EOT and increase in serum bicarbonate greater than or equal to 3 mmol/L from Day 1 without rescue treatment for metabolic acidosis (low bicarbonate) or hyperkalemia. Response was a participant with sK+ within 3.5-5.0 mmol/L and increase in serum bicarbonate greater than or equal to 3 mmol/L at the EOT visit and no use of rescue therapy for hyperkalaemia or low bicarbonate at any point during the randomized placebo-controlled period. Participants who used rescue therapy for low bicarbonate or HK during the randomized placebo-controlled period had last observation prior to rescue therapy carried forward. Participants lost to follow-up prior to EOT visit had response as missing. Logistic regression model included response status (response/non-response) as dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
Time frame: Day 1 to Day 29 of randomization phase
Occurrence (Yes/no) of Patients Having a Normal sK+ Between 3.5 and 5.0 mmol/L Inclusive and Bicarbonate ≥22 mmol/L at Day 29 Without Need for Rescue Treatment for Hyperkalemia or Metabolic Acidosis (Low Bicarbonate)
Response was defined as a participant with sK+ within 3.5-5.0 mmol/L and serum bicarbonate greater than or equal to 22 mmol/L at the EOT visit without the need for rescue therapy for hyperkalaemia or low bicarbonate. Participants who used rescue therapy for hyperkalaemia or low bicarbonate at any point during the randomized placebo-controlled period were assigned a non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
Time frame: Day 1 to Day 29 of randomization phase
Occurrence (Yes/no) of Participants Needing Rescue Treatment for Low Sodium Bicarbonate
Occurrence (yes/no) of participants needing rescue treatment for low sodium bicarbonate any time during the randomized phase
Time frame: Day 1 to Day 29 of randomization phase
| Milestone | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Started | 39 | 0 |
| Completed | 37 | 0 |
| Not completed | 2 | 0 |
| Withdrew: Did not meet randomization criteria for double-blind treatment phase | 1 | 0 |
| Withdrew: Randomized who did not receive treatment | 1 | 0 |
| Milestone | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Started | 17 | 20 |
| Completed | 16 | 15 |
| Not completed | 1 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Missed doses whilst in hospital | 0 | 1 |
| Withdrew: Investigator decision to start rescue therapy for hyperkalemia | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Response was defined as a subject having serum potassium (sK+) within 3.5-5.0 mmol/L at the EOT visit, and no use of rescue therapy for hyperkalaemia at any point during the randomized placebo-controlled period. Participants who used rescue therapy for hyperkalaemia at any point during the randomized placebo-controlled period were assigned a non-response. Participants who died prior to the EOT visit were treated as non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 1 | 15 |
| Response | 15 | 4 |
| Missing | 1 | 1 |
Least-squares mean calculated with a repeated measures analysis of covariance model where the dependent variable was post randomization serum bicarbonate and with fixed terms for randomized treatment group and serum bicarbonate.
| mmol/L | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Mean Serum Bicarbonate at Day 29 | 18.17 ± 0.58 | 16.52 ± 0.56 |
Occurrence (yes/no) of participants having an increase in serum bicarbonate of greater than or equal to 3 mmol/L from baseline (Day 1) to EOT (Day 29) without need for rescue treatment for metabolic acidosis (low bicarbonate). Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 3 mmol/L at the EOT visit without the need for rescue therapy for low bicarbonate. Participants who used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 10 | 16 |
| Response | 6 | 3 |
| Missing | 1 | 1 |
Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 22 mmol/L at the EOT visit without the need for rescue therapy for low bicarbonate. Participants who had used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who died prior to the EOT visit were assigned a non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 14 | 19 |
| Response | 2 | 0 |
| Missing | 1 | 1 |
Response was defined as a participant with an increase in serum bicarbonate greater than or equal to 2 mmol/L at the EOT visit and no use of rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period. Participants who used rescue therapy for low bicarbonate at any point during the randomized placebo-controlled period had their last observation prior to rescue therapy carried forward. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 8 | 13 |
| Response | 8 | 6 |
| Missing | 1 | 1 |
Participants with normal sK+ between 3.5 and 5.0 mmol/L inclusive at EOT and increase in serum bicarbonate greater than or equal to 3 mmol/L from Day 1 without rescue treatment for metabolic acidosis (low bicarbonate) or hyperkalemia. Response was a participant with sK+ within 3.5-5.0 mmol/L and increase in serum bicarbonate greater than or equal to 3 mmol/L at the EOT visit and no use of rescue therapy for hyperkalaemia or low bicarbonate at any point during the randomized placebo-controlled period. Participants who used rescue therapy for low bicarbonate or HK during the randomized placebo-controlled period had last observation prior to rescue therapy carried forward. Participants lost to follow-up prior to EOT visit had response as missing. Logistic regression model included response status (response/non-response) as dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 10 | 18 |
| Response | 6 | 1 |
| Missing | 1 | 1 |
Response was defined as a participant with sK+ within 3.5-5.0 mmol/L and serum bicarbonate greater than or equal to 22 mmol/L at the EOT visit without the need for rescue therapy for hyperkalaemia or low bicarbonate. Participants who used rescue therapy for hyperkalaemia or low bicarbonate at any point during the randomized placebo-controlled period were assigned a non-response. Participants who were lost to follow-up prior to the EOT visit had response treated as missing. Logistic regression model included response status (response / non-response) as the dependent variable and randomized treatment as an independent factor. Participants who died prior to the EOT visit were assigned a non-response.
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| No response | 14 | 19 |
| Response | 2 | 0 |
| Missing | 1 | 1 |
Occurrence (yes/no) of participants needing rescue treatment for low sodium bicarbonate any time during the randomized phase
| Participants | Sodium Zirconium Cyclosilicate (SZC) | Placebo |
|---|---|---|
| Rescue treatment required | 0 | 0 |
| Rescue treatment not required | 17 | 20 |
Collected over Adverse events were collected at screening, during the open-label correction phase (Days 1 and 2), throughout the treatment period of the the randomization phase (Days 2 or 3 to 29 or 30 [end of treatment] or discontinuation), and during the follow up phase (Day 36 to 39).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-Label Phase | 0/38 (0%) | 0/38 (0%) | 1/38 (2.6%) |
| Sodium Zirconium Cyclosilicate (SZC) Double-blind Treatment Phase | 0/17 (0%) | 1/17 (5.9%) | 4/17 (23.5%) |
| Placebo Double-blind Treatment Phase | 1/20 (5%) | 2/20 (10%) | 9/20 (45%) |
| Event | Open-Label Phase | Sodium Zirconium Cyclosilicate (SZC) Double-blind Treatment Phase | Placebo Double-blind Treatment Phase |
|---|---|---|---|
| HypertensionVascular disorders | 0/38 | 1/17 | 0/20 |
| HypervolaemiaMetabolism and nutrition disorders | 0/38 | 0/17 | 1/20 |
| Acute kidney injuryRenal and urinary disorders | 0/38 | 0/17 | 1/20 |
| Event | Open-Label Phase | Sodium Zirconium Cyclosilicate (SZC) Double-blind Treatment Phase | Placebo Double-blind Treatment Phase |
|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 0/38 | 0/17 | 4/20 |
| NauseaGastrointestinal disorders | 0/38 | 0/17 | 2/20 |
| Peripheral swellingGeneral disorders | 0/38 | 1/17 | 0/20 |
| COVID-19Infections and infestations | 0/38 | 1/17 | 0/20 |
| HeadacheNervous system disorders | 0/38 | 1/17 | 0/20 |
| TinnitusEar and labyrinth disorders | 0/38 | 1/17 | 0/20 |
| Vision blurredEye disorders | 0/38 | 1/17 | 0/20 |
| Vitreous floatersEye disorders | 0/38 | 1/17 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/38 | 0/17 | 1/20 |
| Oedema peripheralGeneral disorders | 0/38 | 0/17 | 1/20 |
Full analysis set
| Age, Continuous(years) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Mean | 60.3 ± 16.77 | 65.9 ± 11.13 | 63.3 ± 14.09 |
| Age, Customized(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| >=85 | 0 | 0 | 0 |
| 18-64 | 9 | 9 | 18 |
| 65-84 | 8 | 11 | 19 |
| Sex: Female, Male(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Female | 4 | 8 | 12 |
| Male | 13 | 12 | 25 |
| Race/Ethnicity, Customized(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 4 | 10 |
| Not Hispanic or Latino | 11 | 16 | 27 |
| Race/Ethnicity, Customized(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 1 | 1 |
| White | 14 | 18 | 32 |
| Diabetes status(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| No | 6 | 5 | 11 |
| Yes | 11 | 15 | 26 |
| Chronic Kidney Disease (CKD) Status(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| Stage 3 | 1 | 3 | 4 |
| Stage 4 | 14 | 8 | 22 |
| Stage 5 | 1 | 6 | 7 |
| Missing | 1 | 3 | 4 |
| Chronic Heart Failure Status(Participants) | Sodium Zirconium Cyclosilicate (SZC) | Placebo | Total |
|---|---|---|---|
| No | 17 | 20 | 37 |
| Yes | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2021 to primary completion in Sep 2022, 17 months.
Results were first posted in Oct 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium zirconium cyclosilicate